EUVIMEDEUVIMED entdecken
Multizentrische Studie

PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study

Sanne A M van Lith, Ilanah J Pruis, Nelleke Tolboom, Tom J Snijders, Dylan Henssen, Mark Ter Laan, Maarten Te Dorsthorst, William P J Leenders, Martin Gotthardt, James Nagarajah, Pierre A Robe, Philip De Witt Hamer und 12 weitere

Journal of Nuclear Medicine · 2023-10 · 64 (10) · 1526-1531

DOI: 10.2967/jnumed.123.265738 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 31.08.2023. Verfasst von Sanne A M van Lith und 23 weiteren Autor:innen. Beteiligte Einrichtung: Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Glioblastoma, Prostatic Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Upregulation of prostate-specific membrane antigen (PSMA) in neovasculature has been described in glioblastoma multiforme (GBM), whereas vasculature in nonaffected brain shows hardly any expression of PSMA. It is unclear whether PSMA-targeting tracer uptake on PET is based on PSMA-specific binding to neovasculature or aspecific uptake in tumor. Here, we quantified uptake of various PSMA-targeting tracers in GBM and correlated this with PSMA expression in tumor biopsy samples from the same patients.

Methods

Fourteen patients diagnosed with de novo (n = 8) or recurrent (n = 6) GBM underwent a preoperative PET scan after injection of 1.5 MBq/kg [68Ga]Ga-PSMA-11 (n = 7), 200 MBq of [18F]DCFpyl (n = 3), or 200 MBq of [18F]PSMA-1007 (n = 4). Uptake in tumor and tumor-to-background ratios, with contralateral nonaffected brain as background, were determined. In a subset of patients, PSMA expression levels from different regions in the tumor tissue samples (n = 40), determined using immunohistochemistry (n = 35) or RNA sequencing (n = 13), were correlated with tracer uptake on PET.

Results

Moderate to high (SUVmax, 1.3-20.0) heterogeneous uptake was found in all tumors irrespective of the tracer type used. Uptake in nonaffected brain was low, resulting in high tumor-to-background ratios (6.1-359.0) calculated by dividing SUVmax of tumor by SUVmax of background. Immunohistochemistry showed variable PSMA expression on endothelial cells of tumor microvasculature, as well as on dispersed individual cells (of unknown origin), and granular staining of the neuropil. No correlation was found between in vivo uptake and PSMA expression levels (for immunohistochemistry, r = -0.173, P = 0.320; for RNA, r = -0.033, P = 0.915).

Conclusion

Our results indicate the potential use of various PSMA-targeting tracers in GBM. However, we found no correlation between PSMA expression levels on immunohistochemistry and uptake intensity on PET. Whether this may be explained by methodologic reasons, such as the inability to measure functionally active PSMA with immunohistochemistry, tracer pharmacokinetics, or the contribution of a disturbed blood-brain barrier to tracer retention, should still be investigated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaProstatic NeoplasmsMaleHumansPositron Emission Tomography Computed TomographyGallium RadioisotopesEndothelial CellsProstatePositron-Emission Tomography

Stichwörter der Autor:innen

PETRNA sequencingglioblastomaimmunohistochemistryprostate-specific membrane antigen (PSMA)

Substanzen

Gallium Radioisotopes

Autor:innen und Institutionen

  • Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands.
  • Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Neurology and Neurosurgery, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Neurosurgery, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Biochemistry, Radboud University Medical Center, Nijmegen, The Netherlands.

Zitieren

APA

van Lith, S. A. M., Pruis, I. J., Tolboom, N., Snijders, T. J., Henssen, D., Ter Laan, M., Te Dorsthorst, M., Leenders, W. P. J., Gotthardt, M., Nagarajah, J., Robe, P. A., De Witt Hamer, P., Hendrikse, H., Oprea-Lager, D. E., Yaqub, M., Boellaard, R., Wesseling, P., Balvers, R. K., Verburg, F. A., …, & van de Giessen, E. (2023). PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study. Journal of Nuclear Medicine, 64(10), 1526-1531. https://doi.org/10.2967/jnumed.123.265738

Vancouver

van Lith SAM, Pruis IJ, Tolboom N, Snijders TJ, Henssen D, Ter Laan M, et al. PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study. Journal of Nuclear Medicine. 2023;64(10):1526-1531. doi:10.2967/jnumed.123.265738

BibTeX
@article{vanLith2023,
  author = {van Lith, Sanne A M and Pruis, Ilanah J and Tolboom, Nelleke and Snijders, Tom J and Henssen, Dylan and Ter Laan, Mark and Te Dorsthorst, Maarten and Leenders, William P J and Gotthardt, Martin and Nagarajah, James and Robe, Pierre A and De Witt Hamer, Philip and Hendrikse, Harry and Oprea-Lager, Daniela E and Yaqub, Maqsood and Boellaard, Ronald and Wesseling, Pieter and Balvers, Rutger K and Verburg, Frederik A and Harteveld, Anita A and Smits, Marion and van den Bent, Martin and van Zanten, Sophie E M Veldhuijzen and van de Giessen, Elsmarieke},
  title = {PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {10},
  pages = {1526--1531},
  doi = {10.2967/jnumed.123.265738}
}
Kostenlos starten →